Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) EBT (2022 - 2025)

Entrada Therapeutics has reported EBT over the past 4 years, most recently at -$39.1 million for Q4 2025.

  • Quarterly results put EBT at -$39.1 million for Q4 2025, down 5296.69% from a year ago — trailing twelve months through Dec 2025 was -$142.8 million (down 314.78% YoY), and the annual figure for FY2025 was -$142.8 million, down 314.78%.
  • EBT for Q4 2025 was -$39.1 million at Entrada Therapeutics, up from -$43.5 million in the prior quarter.
  • Over the last five years, EBT for TRDA hit a ceiling of $57.8 million in Q2 2024 and a floor of -$43.5 million in Q3 2025.
  • Median EBT over the past 4 years was -$16.6 million (2024), compared with a mean of -$9.9 million.
  • Biggest five-year swings in EBT: soared 910.98% in 2024 and later crashed 5296.69% in 2025.
  • Entrada Therapeutics' EBT stood at -$24.6 million in 2022, then skyrocketed by 137.34% to $9.2 million in 2023, then plummeted by 107.87% to -$724000.0 in 2024, then crashed by 5296.69% to -$39.1 million in 2025.
  • The last three reported values for EBT were -$39.1 million (Q4 2025), -$43.5 million (Q3 2025), and -$42.9 million (Q2 2025) per Business Quant data.